|
Characteristics
|
Total
|
rs4633 C > T
|
rs4680 G > A
|
rs6269 A > G
|
rs4818 C > G
|
|---|
|
CC
|
CT
|
TT
|
P
|
GG
|
GA
|
AA
|
P
|
AA
|
AG
|
GG
|
P
|
CC
|
CG
|
GG
|
P
|
|---|
|
n
|
143
|
78
|
56
|
9
| |
79
|
56
|
8
| |
62
|
67
|
14
| |
64
|
66
|
13
| |
|
H&Y stageb
|
2.0 ± 1.0
|
2.0 ± 1.5
|
2.0 ± 1.0
|
3.0 ± 0.5
|
0.007**
|
2.0 ± 1.5
|
2.0 ± 1.0
|
2.8 ± 0.5
|
0.01*
|
2.5 ± 1.0
|
2.0 ± 1.0
|
2.0 ± 0.8
|
0.07
|
2.5 ± 1.0
|
2.0 ± 1.0
|
2.0 ± 0.8
|
0.09
|
|
Age onset (years)a
|
59.2 ± 9.2
|
60.7 ± 9.2
|
57.5 ± 9.4
|
57.3 ± 5.6
|
0.01*
|
60.7 ± 9.2
|
57.6 ± 9.4
|
56.8 ± 5.7
|
0.01*
|
59. 5 ± 9.5
|
58.828.6
|
60.3 ± 10.6
|
0.80
|
59.6 ± 9. 5
|
58.6 ± 8.6
|
60.8 ± 10.9
|
0.89
|
|
Disease duration (years)b
|
6.0 ± 5.0
|
6.0 ± 4.0
|
6.0 ± 5.8
|
9.0 ± 7.5
|
0.005**
|
6.0 ± 4.0
|
6.0 ± 6.0
|
8.5 ± 9.5
|
0.005**
|
6.0 ± 5.3
|
6.0 ± 5.0
|
7.5 ± 7.3
|
0.73
|
6.0 ± 5.0
|
6.0 ± 5.0
|
8.0 ± 8.5
|
0.75
|
|
LED (mg)a
|
448.8 ± 327.4
|
386.2 ± 287.5
|
496.8 ± 358.0
|
693.2 ± 322.6
|
0.005**
|
389.5 ± 287.2
|
497.7 ± 358.5
|
692.4 ± 344.8
|
0.007**
|
475.3 ± 399.2
|
425.0 ± 241.7
|
445.5 ± 346.5
|
0.56
|
469.7 ± 396.5
|
435.0 ± 243.6
|
416.4 ± 342.2
|
0.59
|
|
Wearing-off (yes, %)
|
43 (30.1)
|
18 (23.1)
|
19 (33.9)
|
6 (66. 7)
|
0.008**
|
18 (22. 8)
|
20 (35.7)
|
5 (65.1)
|
0.009**
|
20 (32.3)
|
17 (25.4)
|
6 (42.9)
|
0.94
|
20 (31.3)
|
18 (27.3)
|
5 (38.5)
|
0.87
|
|
Dyskinesia (yes, %)b
|
18 (12.6)
|
7 (9.0)
|
9 (16.1)
|
2 (22.2)
|
0.12
|
7 (8.9)
|
9 (16.1)
|
2 (25.0)
|
0.09
|
8 (12.9)
|
7 (10. 5)
|
3 (21.4)
|
0.76
|
8 (12.5)
|
7 (10.6)
|
3 (23.1)
|
0.67
|
|
UPDRS Part I score b
|
2.0 ± 3.0
|
2.0 ± 3.0
|
3.0 ± 3.0
|
2.0 ± 3.0
|
0.92
|
2.0 ± 3.0
|
3.0 ± 3.0
|
2.0 ± 3.5
|
0.91
|
2.0 ± 3.0
|
2.0 ± 3.0
|
3.0 ± 3.0
|
0.41
|
2.0 ± 4.0
|
2.0 ± 3.0
|
3.0 ± 3.0
|
0.31
|
|
UPDRS Part II score b
|
8.0 ± 7.0
|
8.5 ± 9.0
|
8.0 ± 7.3
|
13.0 ± 10.0
|
0.002**
|
8.0 ± 9.0
|
8.0 ± 6.8
|
13.0 ± 7.8
|
0.02*
|
8.0 ± 7.0
|
8.0 ± 8.0
|
11.0 ± 7.3
|
0.48
|
8.0 ± 7.0
|
9.0 ± 7.0
|
9.0 ± 7.5
|
0.70
|
|
UPDRS Part III score a
|
24.7 ± 12.1
|
25.9 ± 11.9
|
21.8 ± 11.6
|
32. 8 ± 12.3
|
0.01*
|
25.8 ± 11.9
|
22.4 ± 12.1
|
31.0011.9
|
0.06
|
25.3 ± 12.3
|
24.2 ± 12.1
|
24.6 ± 11.6
|
0.82
|
24.8 ± 12.3
|
24.4 ± 12.3
|
26.2 ± 10.3
|
0.96
|
|
UPDRS Part IV score b
|
3.0 ± 2.0
|
3.0 ± 2.0
|
2.0 ± 3.0
|
5.0 ± 3.0
|
0.10
|
3.0 ± 2.0
|
2.0 ± 3.8
|
4.5 ± 4.0
|
0.13
|
3.0 ± 4.0
|
2.0 ± 3.0
|
3.0 ± 2.0
|
0.98
|
3.0 ± 4.0
|
2.5 ± 3.0
|
3.0 ± 2.0
|
0.96
|
|
UPDRS total scorea
|
40.0 ± 17.7
|
41.0 ± 17.4
|
36.3 ± 16.5
|
54.8 ± 20.2
|
0.006**
|
40.8 ± 17.3
|
37.1 ± 17.3
|
52.0 ± 19.7
|
0.04*
|
40.7 ± 18.4
|
38.8 ± 17.4
|
42.6 ± 15.8
|
0.79
|
40.2 ± 18.8
|
39.0 ± 17.1
|
44.1 ± 15.5
|
0.81
|
|
NMS scoreb
|
6.0 ± 6.0
|
6.0 ± 6.0
|
6.0 ± 4.8
|
7.0 ± 9.5
|
0.60
|
6.0 ± 6.0
|
6.5 ± 4.8
|
6.5 ± 10.8
|
0.68
|
7.0 ± 6.3
|
6.0 ± 6.0
|
6.5 ± 5.5
|
0.57
|
7.0 ± 7.8
|
6.0 ± 5.3
|
6.0 ± 6.0
|
0.38
|
|
HAMA scoreb
|
4.0 ± 6.0
|
4.0 ± 6.0
|
5.0 ± 4.5
|
4.0 ± 14.0
|
0.48
|
4.0 ± 6.0
|
5.0 ± 4.8
|
4.5 ± 13.3
|
0.40
|
5.0 ± 6.0
|
4.0 ± 4.0
|
6.0 ± 7.0
|
0.85
|
5.0 ± 6.0
|
4.0 ± 4.0
|
6.0 ± 6.0
|
0.93
|
|
HAMD scoreb
|
3.0 ± 4.0
|
2.0 ± 5.0
|
4.0 ± 4.0
|
4.0 ± 6.0
|
0.40
|
2.0 ± 5.0
|
4.0 ± 4.0
|
3.0 ± 6.5
|
0.20
|
2.0 ± 6.3
|
3.0 ± 4.0
|
2.0 ± 3.8
|
0.14
|
2.0 ± 7.0
|
3.0 ± 4.0
|
2.0 ± 2.0
|
0.41
|
|
MMSE scoreb
|
28.0 ± 3.0
|
28.0 ± 3.0
|
28.0 ± 3.0
|
27.0 ± 4.0
|
0.49
|
28.0 ± 3.0
|
28.0 ± 3.0
|
27.5 ± 3.0
|
0.54
|
28.0 ± 3.0
|
28.0 ± 3.0
|
28.0 ± 3.5
|
0.12
|
28.0 ± 3.0
|
28.0 ± 3.0
|
28.0 ± 3.5
|
0.13
|
- Data were analyzed with analysis of variance of factorial design with age and sex as covariates
- Binary logistic regression model was used to analyze the relation between SNP and motor complication (wearing-off phenomenon and dyskinesia), with age and sex as covariates
- *P < 0.05 **P < 0.01
-
aValues are expressed as the mean ± SD
-
bValues are expressed as the median ± IQ
